Evonik stock: third-quarter report on November 3, 2026, slightly lower pre-market
Published on 10/20/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting schedule and market setup
- Evonik's third-quarter update is scheduled for November 3, 2026.
- The investor-relations calendar lists the fourth-quarter 2026 report for March 4, 2027.
- Evonik stock trades pre-market at EUR 21.20 at 8:16 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.66 percent below the Xetra close of October 19, 2026.
Evonik's investor-relations calendar schedules the company's third-quarter 2026 report for November 3, 2026. Evonik stock trades pre-market at EUR 21.20 at 8:16 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.66 percent below the Xetra close of October 19, 2026 (EUR 21.34).
Next company reporting date
The scheduled publication concerns Evonik's business development in the third quarter of 2026. The date is listed in the company's investor-relations calendar, which also identifies the reporting event as an online, on-demand presentation. The calendar is maintained by Evonik.
Ahead of the Xetra open
The indication is EUR 0.14 below the reference close. Bid and ask prices are EUR 21.18 and EUR 21.22, respectively. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Evonik stock.
Evonik's business and calendar
Evonik's activities include development and production services for pharmaceutical and biotechnology customers, including lipid-based drug-delivery products, according to its investor-relations information. The same calendar lists the fourth-quarter 2026 report for March 4, 2027. Market context: Market report DAX.
